Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Autoimmune disease

Systemic lupus erythematosus (SLE)

Solute carrier family 15 member 4 (SLC15A4; PHT1)

Mouse studies suggest antagonizing SLC15A4 could help treat SLE. In a mouse model for SLE, a loss-of-function mutation in Slc15a4 prolonged survival and decreased type I interferon and autoimmune antibody production compared with what was seen in mice with wild-type Slc15a4. Next steps include developing a high throughput assay for inhibitors of SLC15A4 or its interaction with endosomal toll-like receptors (TLRs), which are thought to mediate the effects of SLC15A4 activity.

SciBX 6(8); doi:10.1038/scibx.2013.184
Published online Feb. 28, 2013

Patent pending; licensed to an undisclosed company

Baccala, R. et al. Proc. Natl. Acad. Sci. USA; published online Feb. 4,
2013;
doi:10.1073/pnas.1222798110
Contact: Argyrios N. Theofilopoulos, The Scripps Research Institute, La Jolla, Calif.
e-mail:
argyrio@scripps.edu

Contact: Roberto Baccala, same affiliation as above
e-mail:
rbaccala@scripps.edu

Contact: Bruce Beutler, The University of Texas Southwestern Medical Center, Dallas, Texas
e-mail:
bruce.beutler@utsouthwestern.edu